Trials Sponsors Conditions Drugs Pricing

Conditions

Autosomal Dominant Polycystic Kidney Disease

Keywords

Oxidative StressMitochondria injury and functionNADPH oxidase 4

Outcome Measures

Primary Outcomes (5)

NOX4 levels
Determination of NOX4 levels from urine and plasma samples
Baseline
mtDNA copy number
Determination of mtDNA copy number from urine and plasma samples
Baseline
Tricarboxylic Acid (TCA) cycle metabolites
Determination of TCA cycle metabolite concentration from urine and plasma samples
Baseline
REDOX status
Determination of REDOX from urine and plasma samples
Baseline
Total kidney volume (TKV)
Determined by MRI
Baseline

Secondary Outcomes (1)

Estimated Glomerular Filtration Rate (eGFR)
Baseline

Study Arms (1)

Patients with a previous diagnosis of ADPKD

Patients that have been diagnosed with ADPKD and are classified as Class 1A, 1B, 1C, 1D and 1E.

Eligibility Criteria

Age15 Years - 40 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64)

Sampling MethodProbability Sample

Study Population

Male and female patients with a previous diagnosis of ADPKD

You may qualify if:

ADPKD (based on Ravine et al. criteria)

Sponsors & Collaborators

Polycystic Kidney Disease Foundation
Othercollaborator
Mayo Clinic
Otherlead

Study Sites (1)

Mayo Clinic

Rochester, Minnesota, 55905, United States

RECRUITING

Ahmed AbdelfattahCONTACTAbdelfattah.Ahmed@mayo.edu

Maria V Irazabal, M.D., Ph.D.CONTACT507-884-5628 irazabalmira.maria@mayo.edu

Maria V Irazabal, M.D., Ph.D.PRINCIPAL INVESTIGATOR

Biospecimen

Retention: SAMPLES WITH DNA

Urine and plasma samples

MeSH Terms

Conditions

Polycystic Kidney, Autosomal Dominant

Condition Hierarchy (Ancestors)

Polycystic Kidney DiseasesKidney Diseases, CysticKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesAbnormalities, MultipleCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesCiliopathiesGenetic Diseases, Inborn

Study Officials

Maria V Irazabal, M.D., Ph.D.
Mayo Clinic
PRINCIPAL INVESTIGATOR

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: CROSS SECTIONAL
Target Duration: 2 Years
Sponsor Type: OTHER
Responsible Party: PRINCIPAL INVESTIGATOR
PI Title: Principal Investigator

Study Record Dates

First Submitted

November 10, 2020

First Posted

November 16, 2020

Study Start

July 21, 2020

Actual (reported)

Primary Completion

December 2026

Estimated

NOX4 and Related Biomarkers in ADPKD

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (1)

Study Arms (1)

Patients with a previous diagnosis of ADPKD

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (5)

Secondary Outcomes (1)

Study Arms (1)

Patients with a previous diagnosis of ADPKD

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Locations